Finanzen von Carisma Therapeutics Inc (CARM)CARMCarisma Therapeutics Inc

Carisma Therapeutics Inc (CARM) generates its revenue primarily from Protein Therapeutics, which accounts for 100.0% of total sales, equivalent to $20.00M. Understanding this concentration is critical for investors evaluating how CARM navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Carisma Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -405.26%, while the net margin is -510.59%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CARM converts its operational activities into shareholder value.

In the context of the broader market, CARM competes directly with industry leaders such as ENSC and PLRZ. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CARM's gross margin of 100.00% stands against ENSC's 100.00% and PLRZ's N/A. Such benchmarking helps identify whether Carisma Therapeutics Inc is trading at a premium or discount relative to its financial performance.